Updated St. Gallen International Breast Cancer Guidelines, for the Second Time, Recognize Oncotype DX® as the Only Validated

  Updated St. Gallen International Breast Cancer Guidelines, for the Second
  Time, Recognize Oncotype DX® as the Only Validated Multi-Gene Test Able to
                         Predict Chemotherapy Benefit

  PR Newswire

  GENEVA and REDWOOD CITY, California, Aug. 23, 2013

-- The 13th St. Gallen International Expert Consensus Panel Report Emphasizes
Oncotype DX's Unsurpassed Clinical Validation Supporting Greater Use and
Reimbursement of the Test Worldwide

GENEVA and REDWOOD CITY, California, Aug. 23, 2013 /PRNewswire/ --Genomic
Health, Inc. (Nasdaq: GHDX) today announced that the 13th St. Gallen
International Breast Cancer Conference Expert Panel, for the second time,
recognized the Oncotype DX ® breast cancer test for its ability to provide
not only prognostic information, but also predictive information regarding the
benefit from chemotherapy for patients with early-stage endocrine sensitive
invasive breast cancer. Oncotype DX was the only multi-gene test accepted with
a strong majority of panelists supporting it as both a prognostic and
predictive tool, which led to "a recommendation that selection of patients who
might forego chemotherapy could be based on the 21-gene Recurrence Score."
The new guidelines have been recently published online in the Advance Access
section of Annals of Oncology and will appear in a future print issue.

(Logo: http://photos.prnewswire.com/prnh/20130425/SF01493LOGO )

"We are pleased that this expert panel recognizes the unsurpassed clinical
evidence of Oncotype DX as the only test validated to answer the important
question of which estrogen receptor-positive breast cancer patients need
chemotherapy in addition to hormonal therapy," said Steven Shak, M.D. , chief
medical officer and executive vice president of research and development,
Genomic Health. "Physicians in more than 70 countries have used Oncotype DX
for treatment planning in more than 375,000 patients to date, enabling
patients to make more informed decisions and healthcare systems to avoid

The updated guidelines, which are reviewed bi-annually, reflect increasing
support for the use of multi-gene tests to provide physicians and patients
with information that goes beyond traditional clinic-pathologic measures to
enable better informed treatment decisions. The guidelines also reference
that the use of the Oncotype DX breast cancer test is either cost-effective or
provides cost savings in all markets analyzed.

"The growing acceptance of utilizing genomics as an integral treatment
decision tool is an important milestone to improve the treatment of breast
cancer overall," said Martine Piccart, M.D., chief of the Medicine Department
at the Jules Bordet Institute in Brussels, Belgium, member of the St. Gallen
International Breast Cancer Expert Panel, and president of the European
Society of Molecular Oncology (ESMO). "The panel acknowledges the added value
that genomic assays can provide and encourages broader availability for these
assays so that more patients can benefit from them. As we mark the tenth
anniversary of the first full sequencing of the human genome, we will continue
our efforts to enhance breast cancer care around the world."

The Oncotype DX breast cancer test has been evaluated in 15 clinical studies
involving more than 6,000 patients, and is the only genomic assay to meet
level 1B evidence (Simon RM, Paik S, and Hayes DF. JNCI 2009) for clinical use
in early-stage, hormone receptor-positive, invasive, breast cancer patients
both as a prognosticator and predictor of likelihood of benefit from
chemotherapy. Separately, with more than 18 decision impact studies conducted
in 10 countries, the test has consistently been demonstrated to change
treatment recommendations in about 30 percent of early-stage invasive breast
cancer patients, reinforcing its clinical validation, accuracy and precision.
Additionally, more than 20 health economic analyses conducted in Europe, Asia,
Israel, and North America demonstrate that the Oncotype DX test is cost
effective and, in some countries, delivers significant healthcare savings,
reinforcing the test's economic value across multiple health care systems.

About Genomic Health

Genomic Health , Inc. (NASDAQ: GHDX) is a global healthcare company that
provides actionable genomic information to personalize cancer treatment
decisions. The company's lead product, the Oncotype DX® breast cancer test ,
has been shown to predict the likelihood of chemotherapy benefit as well as
recurrence in invasive breast cancer and has been shown to predict the
likelihood of recurrence in ductal carcinoma in situ (DCIS) . In addition to
this widely adopted test, Genomic Health provides the Oncotype DX colon cancer
test , the first multi-gene expression test developed for the assessment of
risk of recurrence in patients with stage II and stage III disease, and the
Oncotype DX prostate cancer test , which predicts disease aggressiveness in
men with low risk disease. As of June 30, 2013, more than 19,000 physicians in
over 70 countries had ordered more than 375,000 Oncotype DX tests. Genomic
Health has a robust pipeline focused on developing tests to further optimize
the treatment of breast, colon and prostate cancers, as well as the treatment
of renal cancer. The company is based in Redwood City , California with
European headquarters in Geneva, Switzerland. For more information, please
visit, www.GenomicHealth.com and follow the company on Twitter: @GenomicHealth
. To learn more about Oncotype DX tests , visit: www.OncotypeDX.com ,
www.mybreastcancertreatment.org and www.myprostatecancertreatment.org . 

This press release contains forward-looking statements within the meaning of
the Private Securities Litigation Reform Act of 1995, including statements
relating to the belief that the Oncotype DX is unique in its ability to
predict chemotherapy benefit in early stage breast cancer; the company's
belief that the Oncotype DX Recurrence Score cannot be predicted by other
factors such as age or individual biomarkers; the company's belief that the
Oncotype DX is cost effective and can reduce the cost of treatment in various
health systems around the world; the company's belief that it has the
opportunity to advance the quality of cancer treatment decisions and that the
inclusion of Oncotype DX in the St. Gallen guidelines will enable greater
international utilization of Oncotype DX; the applicability of study results
to actual outcomes; the ability of the company's tests to impact clinical
practice; and the focus and attributes of the company's product pipeline.
Forward-looking statements are subject to risks and uncertainties that could
cause actual results to differ materially, and reported results should not be
considered as an indication of future performance. These risks and
uncertainties include, but are not limited to: risks related to the success of
the company's colon and prostate cancer tests; the company's ability to
increase usage of its tests; the risk that the company may not obtain or
maintain sufficient levels of reimbursement, domestically or abroad, for its
existing tests and any future tests it may develop; ; the risks and
uncertainties associated with regulation of the company's tests by the FDA and
other regulatory organizations; the company's ability to compete against third
parties; the company's ability to develop and commercialize new tests;
unanticipated costs or delays in research and development efforts; ; the
company's ability to successfully commercialize its tests outside of the
United States; the results of clinical studies; the applicability of clinical
study results to actual outcomes; and the other risks set forth in the
company's filings with the Securities and Exchange Commission, including the
risks set forth in the company's Quarterly Report on Form 10-Q for the quarter
ended June 30, 2013. These forward- looking statements speak only as of the
date hereof. Genomic Health disclaims any obligation to update these
forward-looking statements.

NOTE: The Genomic Health logo, Oncotype, Oncotype DX, Recurrence Score and
DCIS Score are trademarks or registered trademarks of Genomic Health, Inc. All
other trademarks and service marks are the property of their respective

Website: http://www.genomichealth.com
Contact: Investors: Dean Schorno, Genomic Health, +1-650-569-2281,
investors@genomichealth.com; or Media: Victoria Steiner, Genomic Health,
+1-415-370-5804, media@genomichealth.com
Press spacebar to pause and continue. Press esc to stop.